Off-label treatment with Imbruvica (ibrutinib), a lymphoma and leukemia therapy, can reduce the anemia and peripheral symptoms of cold agglutinin disease (CAD), a preliminary study has found. The study, “Effective Treatment of Cold Agglutinin Disease/Cold…
News
Use of the investigational therapy sutimlimab results in substantial reductions in patient hospitalizations and blood transfusions among adults with primary cold agglutinin disease (CAD), a post hoc analysis of the CARDINAL trial found. The results of the analysis point…
Cold agglutinin disease (CAD) disease negatively affects a variety of aspects of daily living, with patients often experiencing fatigue, according to new research. In a separate study, it was found that CAD patients appear to be at an increased risk of anxiety or depression. Researchers from Sanofi…
To empower and equip members of the rare disease community to engage state leaders in matters of importance to patients and their families, the National Organization for Rare Disorders (NORD) has launched an initiative across the U.S. Its goal is to establish a Rare Disease Advisory Council (RDAC)…
The first wave of COVID-19 in Europe severely disrupted access to care and raised stress and anxiety in people with rare diseases, negatively affecting their health and well-being, according to a survey conducted by Eurordis-Rare Diseases Europe. “People living with rare diseases in Europe have found themselves caught as collateral…
The U.S. Food and Drug Administration (FDA) has issued a complete response to Sanofi’s application requesting that its investigational therapy sutimlimab be approved for treating hemolysis — the breakdown of red blood cells — in adults with cold agglutinin disease (CAD), the company announced in…
Leaders in the U.S. rare disease community came together recently for a webinar to present helpful information on how to start a nonprofit and patient registry. They shared about how their respective organizations came to be, as well as the benefits of creating patient registries and how they can help…
People with non-Hodgkin’s lymphoma (NHL) — a type of blood cancer — that co-occurs with autoimmune hemolytic anemia (AIHA) have a poor prognosis, suggesting a need for further research into this rare combination of conditions, a case report highlights. The case was reported at the 2020 Lymphoma,…
Apellis Pharmaceuticals and Swedish Orphan Biovitrum (Sobi) are collaborating to advance the development of systemic pegcetacoplan, or APL-2, in the treatment of cold agglutinin disease (CAD) and other disorders, the companies announced in a press release. Pegcetacoplan is an investigational therapy designed to limit activation of…
The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of free virtual workshops in December, with the aim of empowering leaders to start non-profit organizations and research programs to help people with rare diseases. “The RareLaunch program is…
Recent Posts
- For US woman, CAD exacerbates iron disorder, leading to liver damage
- Post-exertional malaise leads to a cycle of crashes and comebacks
- Enjaymo provides lasting CAD control even with fewer doses: Study
- Being vigilant during transfusions brings me a vital victory
- Rituximab helps treat CAD linked to long-term immunosuppression: Case
- With my health from CAD steadily declining, I call in the cavalry, part 3
- Rituximab effective in rare dual autoimmune blood disorder case
- Unexplained anemia in seniors may signal autoimmune disease CAD
- With my health from CAD steadily declining, I call in the cavalry, part 2
- FDA fast-tracks potential new option for autoimmune blood diseases